4565.T) announced">
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Governance sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 13, 2026 Nxera Pharma Co.,Ltd. [4565.T] TOKYO, Feb 13 (Pulse News Wire) – Nxera Pharma Co.,Ltd. (4565.T) announced changes to its executive leadership effective February 13, 2026. * Key changes: * President: 代表者 代表執行役社長CEO * Director: 諸岡 健雄氏を社外取締役候補に選任 * Director: 関 美和氏、永井 智亮氏は取締役を退任 * Director: ネクセラファーマ株式会社(以下「当社」)は、2026年2月13日開催の取締役会において、取締役の異動につ * Director: いて決議しましたので、以下の通りお知らせいたします。取締役候補者は、指名委員会の決議に基づき決定され * Director: なお、本件は2026年3月25日開催予定の